• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Zymergen Inc.

    10/19/22 12:25:02 PM ET
    $ZY
    Industrial Specialties
    Industrials
    Get the next $ZY alert in real time by email
    S-8 POS 1 d414279ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on October 19, 2022

    Registration No. 333-255450

    Registration No. 333-263979

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    Form S-8 Registration Statement No. 333-255450

    Form S-8 Registration Statement No. 333-263979

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ZYMERGEN INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   46-2942439

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

    5959 Horton Street, Suite 700

    Emeryville, California 94608

    (415) 801-8073

    (Address, including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

    Zymergen Inc. 2021 Incentive Award Plan

    Zymergen Inc. Employee Stock Purchase Plan

    (Full Title of the Plans)

    Enakshi Singh

    Chief Financial Officer

    5959 Horton Street, Suite 700

    Emeryville, California 94608

    Telephone: (415) 801-8073

    (Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service)

     

     

    with a copy to:

    Marko Zatylny

    Ropes & Gray LLP

    Prudential Tower

    800 Boylston Street

    Boston, MA 02199

    (617) 951-7000

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐     
    Accelerated filer   ☐    Smaller reporting company   ☒
    Non-accelerated filer   ☒    Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF UNSOLD SECURITIES

    This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by Zymergen Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “SEC”):

     

      1.

    Registration Statement on Form S-8 (File No. 333- 255450), originally filed with the SEC on April 23, 2021, pertaining to the registration of (i) 6,364,099 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) for issuance under the Company’s 2014 Stock Plan; (ii) 10,770,034 shares of Common Stock for issuance under the Company’s 2021 Incentive Award Plan (the “2021 Plan”); and (iii) 2,154,006 shares of Common Stock for issuance under the Company’s Employee Stock Purchase Plan (the “ESPP”); and

     

      2.

    Registration Statement on Form S-8 (File No. 333-263979), originally filed with the SEC on March 30, 2022, pertaining to the registration of (i) 5,152,264 additional shares of Common Stock for issuance under the 2021 Plan, and (ii) 1,030,452 additional shares of Common Stock for issuance under the ESPP.

    On October 19, 2022, pursuant to the Agreement and Plan of Merger dated as of July 24, 2022 (the “Merger Agreement”), by and among Ginkgo Bioworks Holdings, Inc., a Delaware corporation (“Parent”), Pepper Merger Subsidiary Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”), and the Company, Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

    As a result of the Merger and the related transactions contemplated by the Merger Agreement, the Company has terminated any and all offerings of the Company’s securities pursuant to the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered but unsold or otherwise unissued under the Registration Statements, if any, as of the date hereof. The Registration Statements are hereby amended to reflect the deregistration of such securities, and the Company hereby terminates the effectiveness of the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on October 19, 2022. No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

    ZYMERGEN INC.
    By:  

    /s/ Enakshi Singh

    Name:   Enakshi Singh
    Title:   Chief Financial Officer
    Get the next $ZY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZY

    DatePrice TargetRatingAnalyst
    3/2/2022Market Perform
    Cowen
    1/12/2022$6.50Reduce → Hold
    HSBC Securities
    10/15/2021Market Perform
    Cowen
    9/27/2021$12.00Neutral → Underweight
    JP Morgan
    8/31/2021$56.00 → $13.00Buy → Neutral
    UBS
    8/4/2021$43.00 → $7.00Buy → Underperform
    BofA Securities
    8/4/2021Outperform → Market Perform
    Cowen & Co.
    8/4/2021$55.00 → $12.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $ZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    3/2/22 8:44:04 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Zymergen from Reduce to Hold and set a new price target of $6.50

    1/12/22 7:08:41 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    10/15/21 7:34:23 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks Completes Acquisition of Zymergen

    BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t

    10/19/22 9:08:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

    EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l

    7/14/22 4:56:39 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    SEC Filings

    View All

    SEC Form 15-12G filed by Zymergen Inc.

    15-12G - Zymergen Inc. (0001645842) (Filer)

    10/31/22 4:47:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form EFFECT filed by Zymergen Inc.

    EFFECT - Zymergen Inc. (0001645842) (Filer)

    10/26/22 12:15:12 AM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form POS AM filed by Zymergen Inc.

    POS AM - Zymergen Inc. (0001645842) (Filer)

    10/19/22 12:36:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/21/22 4:30:20 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:17:59 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:15:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Financials

    Live finance-specific insights

    View All

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Reports Preliminary First Quarter 2022 Financial Results

    EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r

    5/12/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

    EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest

    4/13/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

    SC 13G/A - Zymergen Inc. (0001645842) (Subject)

    10/21/22 4:31:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 3:22:50 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 9:36:54 AM ET
    $ZY
    Industrial Specialties
    Industrials